Czechia’s medical cannabis programme gains momentum as GP reform widens access
Czechia’s medical cannabis programme grew 46% in 2025—the strongest year since 2021. Full-year SÚKL data confirms the GP reform partially worked: prescribing doctors rose 28% to 305, flower grew 35% (233 → 314 kg), and the extract market more than doubled (30 → 76 kg). Domestic EU-GMP producers now anchor supply, while Czech infrastructure increasingly […]
Legalisation Momentum Meets Regulatory Headwinds — October 2025 Brief
Access the database with +5,000 regulation updates, market reports and science papers on the international cannabis market. October 2025 highlighted a decisive shift toward regulatory expansion across the global cannabis landscape. Import quotas rose, hospital and pharmacy access widened, and several countries advanced long-awaited legal frameworks — signalling renewed political momentum. Yet these openings coexist with […]
Spain’s CBD Boom Faces Hemp Sector Collapse and Regulatory Limbo
Between 2018 and 2023, Spain built one of Europe’s most dynamic CBD consumer markets. Revenues more than doubled, specialist shops appeared in every large city, and Spanish brands started exporting to neighbouring countries. Yet in the same period, the country almost eradicated the hemp crops that should be feeding that demand. What should be a […]
Spain Legalises Medical Cannabis: Patient Access Is the Next Frontier
After years of political delay and institutional hesitation, Spain has finally taken a decisive step toward a regulated medical cannabis system. Royal Decree 903/2025, published this summer, establishes the country’s first comprehensive framework for therapeutic use — a turning point that begins to align Spain with other advanced European markets. This article examines the foundations […]
Regulatory scrutiny fuels market instability — September 2025 Brief
September 2025 underscored the tension between rising demand and tightening compliance across global cannabis supply chains. Imports, prescriptions, and economic contributions continue to climb, yet regulatory reviews multiply — with stricter prescribing rules and compliance crackdowns reshaping access. Some countries move boldly toward reform, while others drift in regulatory grey zones — marking a sector entering […]
Australia’s Cannabis Market Transition: Booming Supply, Tightening Rules
Australia’s medical cannabis market continues to grow at an impressive pace, yet it faces a series of regulatory, clinical, and supply-side inflection points that are shaping the sector’s trajectory. Despite a growing scale and further maturation of the market, challenges remain in terms of patient safety, prescriber oversight, and domestic supply competitiveness. This feature article […]
Global Market Grows Under Tightening Rules – August 2025 Brief
Diverging access and mounting constraints define the next phase of global cannabis amid fragile supply chains.
The Transatlantic Cannabis Triangle: Canada, Portugal & Germany Under Pressure
Germany has rapidly become the world’s leading medical cannabis market since legalisation in April 2024. Imports more than doubled from 32.5 tonnes in 2023 to 71.6 tonnes in 2024. The second quarter of 2025 alone saw imports of 43 tonnes, with over 132 tonnes imported in the last 4 quarters. Current projections suggest Germany could […]
Momentum Builds Unevenly in Global Cannabis Reform — July 2025 Brief
This month’s brief captures a pivotal moment in the global cannabis sector, as reform momentum continues but faces intensifying regulatory headwinds. Governments are tightening oversight on prescribing and distribution — with telemedicine under the spotlight in Germany and Australia — as markets adapt to shifting access models and research adds fresh weight to the public […]
The Sleeping Giant Awakes: France’s Chance to Lead Medical Cannabis
After a decade of cautious experimentation, France’s medical cannabis program has treated over 3,200 patients and shown strong safety, efficacy, and public support. But with fragile supply chains, high dropout rates, and policy delays, the country now faces a choice: align policy, production, and access to build a sustainable, sovereign industry — or risk falling […]